Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
ABEO filed a Rule 144 notice reporting proposed resale activity in its Common Stock. The notice shows 18,160 shares sold on 06/15/2026 for $103,695.00 and lists a Common Stock outstanding figure of 56,995,144 shares as of 07/06/2026. The securities reported trace to an equity compensation grant dated 05/20/2020.
Abeona Therapeutics director Alland Leila reported an open-market sale of company stock. On this Form 4, Leila sold 11,000 shares of Abeona Therapeutics common stock in a non-derivative, open-market transaction at a weighted average price of $5.917 per share.
The sale occurred through multiple trades on a single day at prices ranging from $5.915 to $5.9334 per share. After these transactions, Leila directly holds 162,614 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada reported a routine compensation-related share adjustment. On a Form 4 dated for a transaction on June 16, 2026, 222 shares of common stock at $5.67 per share were withheld to satisfy tax obligations upon vesting of restricted stock awards. Following this withholding, he holds 303,229 common shares directly.
ABEONA THERAPEUTICS INC. director Christine Berni Silverstein reported an open-market sale of 18,160 shares of common stock. The shares were sold at a weighted average price of $5.7101 per share. According to the footnotes, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After the transaction, she directly owned 119,562 shares of Abeona common stock.
Abeona Therapeutics Inc. reported results of its annual stockholder meeting held virtually on June 12, 2026. Stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors to serve until the 2029 annual meeting. They approved, on an advisory basis, the compensation of named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved increasing shares reserved for issuance under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000. A proposed amendment to remove the advance notice provision for director nominations from the certificate of incorporation received a majority of votes cast but did not obtain the required 66 2/3% of outstanding shares and therefore was not approved.
Abeona Therapeutics Inc. reported that board member Michael Amoroso resigned from its Board of Directors effective June 11, 2026. Along with leaving the board, he also stepped down from the Board’s Nominating and Corporate Governance Committee.
The company stated that Mr. Amoroso’s resignation was for personal reasons and was not due to any disagreement with Abeona regarding its operations, policies, or practices. The filing was signed on behalf of the company by Chief Financial Officer Joseph Vazzano.
Abeona Therapeutics Inc. filed a current report to share that it has prepared an updated investor presentation. The company plans to use this presentation in meetings with investors, analysts, and other interested parties.
The investor presentation, dated June 10, 2026, is furnished as Exhibit 99.1 under Regulation FD. Abeona notes that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O’Malley reported small stock sales primarily to cover taxes on vested awards. He sold 4,826 shares of common stock at a weighted average price of $5.4295 on June 8, 2026 and 6,305 shares at $5.3042 on June 9, 2026, totaling 11,131 shares. A footnote states the sales were made to cover tax obligations from vesting of restricted stock awards. After these transactions, he directly owned 440,003 shares of Abeona common stock.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano reported selling a total of 49,338 shares of common stock in open-market transactions on June 8–9, 2026 at weighted average prices around $5.30–$5.43 per share. According to the disclosure, these sales were made to cover tax obligations arising from the vesting of restricted stock awards and were carried out under a Rule 10b5-1 trading plan adopted on January 21, 2026. Following the transactions, Vazzano directly holds 518,437 shares of Abeona Therapeutics common stock.